# A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects

> **NCT06669429** · PHASE1 · RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** RS-C1001
- **DRUG:** RS-C1001
- **DRUG:** RS-C1001
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06669429
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669429, "A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06669429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*